How an Obesity Drug Could Help Alcohol Use Disorder
Promising preclinical and early clinical data suggest a role for GLP-1 receptor agonist therapy in treating alcohol use disorder.
Stay updated with breaking news from Ingle Blind Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Promising preclinical and early clinical data suggest a role for GLP-1 receptor agonist therapy in treating alcohol use disorder.
Restarting a CGRP monoclonal antibody (mAb) after a gap in treatment may lower response rate, a new study suggests. However, switching to a different mAb may counter this effect.
Famed microbiome researcher Dr Martin J. Blaser shares what he sees as the most promising applications, and the rigorous clinical trials needed to realize them.
Findings from a large US cohort study show comparable accuracy, but better discrimination of patients across disease stages.
Experts urge rigorous research due to safety concerns and uncertainties and prefer naloxone as the preferred first-line agent.